ProQR Signs Exclusive Worldwide License Agreement with Ionis for IONIS-RHO-2.5 Candidate (now QR-1123)

Shots:

• Ionis Pharmaceuticals will receive an upfront payment in ordinary shares $2.5M, $22.23/share representing 20% premium plus milestones payments and 20% royalties on net sales of QR-1123. ProQR to get WW license rights for Ionis’ IONIS-RHO-2.5 Candidate
• In 2019, ProQR plans onset of P-I/II trial for QR-1123 in autosomal dominant retinitis pigmentosa (adRP) with awaited IND approval from the US FDA
• Ionis’ QR-1123 IV a novel RNA drug, developed by using its own technology indicated in adRP

Click here to read full press release/ article | Ref: ProQR Therapeutics Image:Trout Access